Theravance Biopharma (NASDAQ:TBPH) Share Price Passes Below 200 Day Moving Average – Here’s What Happened

Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) passed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $8.77 and traded as low as $8.56. Theravance Biopharma shares last traded at $8.80, with a volume of 102,008 shares traded.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on TBPH shares. HC Wainwright reaffirmed a “buy” rating and issued a $15.00 target price on shares of Theravance Biopharma in a research report on Monday, September 16th. TD Cowen lowered their target price on Theravance Biopharma from $10.00 to $9.00 and set a “hold” rating on the stock in a research report on Tuesday, August 6th. StockNews.com cut Theravance Biopharma from a “buy” rating to a “hold” rating in a research report on Saturday, August 10th. Leerink Partnrs lowered Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 6th. Finally, Leerink Partners downgraded Theravance Biopharma from an “outperform” rating to a “market perform” rating and cut their price objective for the company from $15.00 to $10.00 in a report on Tuesday, August 6th. Four research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $13.75.

Theravance Biopharma Price Performance

The business has a 50-day simple moving average of $8.18 and a two-hundred day simple moving average of $8.77. The stock has a market cap of $427.97 million, a price-to-earnings ratio of -10.23 and a beta of 0.25.

Theravance Biopharma (NASDAQ:TBPH) last posted its earnings results on Monday, August 5th. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.25). Theravance Biopharma had a negative return on equity of 21.29% and a negative net margin of 73.61%. The business had revenue of $14.26 million for the quarter, compared to analyst estimates of $15.81 million. During the same period in the previous year, the firm posted ($0.28) earnings per share. As a group, equities analysts anticipate that Theravance Biopharma, Inc. will post -1.04 earnings per share for the current fiscal year.

Insider Buying and Selling at Theravance Biopharma

In related news, major shareholder Eli Samaha bought 999,800 shares of the business’s stock in a transaction dated Wednesday, August 7th. The stock was bought at an average price of $7.80 per share, for a total transaction of $7,798,440.00. Following the purchase, the insider now owns 9,511,150 shares in the company, valued at $74,186,970. This represents a 0.00 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 6.90% of the company’s stock.

Institutional Trading of Theravance Biopharma

Hedge funds have recently added to or reduced their stakes in the company. Wellington Management Group LLP increased its position in Theravance Biopharma by 68.0% during the 4th quarter. Wellington Management Group LLP now owns 287,102 shares of the biopharmaceutical company’s stock worth $3,227,000 after buying an additional 116,164 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its stake in Theravance Biopharma by 16.6% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 52,876 shares of the biopharmaceutical company’s stock worth $474,000 after purchasing an additional 7,509 shares in the last quarter. BNP Paribas Financial Markets boosted its holdings in Theravance Biopharma by 30.7% in the 1st quarter. BNP Paribas Financial Markets now owns 33,458 shares of the biopharmaceutical company’s stock valued at $300,000 after purchasing an additional 7,851 shares during the period. SG Americas Securities LLC grew its position in shares of Theravance Biopharma by 6.3% during the 1st quarter. SG Americas Securities LLC now owns 209,566 shares of the biopharmaceutical company’s stock worth $1,880,000 after purchasing an additional 12,460 shares in the last quarter. Finally, Russell Investments Group Ltd. increased its holdings in shares of Theravance Biopharma by 55.7% during the first quarter. Russell Investments Group Ltd. now owns 45,114 shares of the biopharmaceutical company’s stock worth $405,000 after purchasing an additional 16,135 shares during the period. 99.10% of the stock is owned by institutional investors and hedge funds.

About Theravance Biopharma

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.